The Efficacy and Safety of a Chinese Herbal Medicine for Long COVID Associated Fatigue

• Status: Not yet recruiting
• Trial end date: 2024-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double-blinded, placebo-controlled clinical trial to determine the efficacy and safety of a Chinese herbal medicine (Shenlingcao oral liquid) for treating long COVID associated fatigue.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hong Kong Baptist University
• Collaborator: China Resources Jiangzhong Pharmaceutical Co.,Ltd.

Criteria

Inclusion Criteria:

1. 18-65 years adults

2. Fulfill the long COVID diagnostic criteria by Centers for Disease Control and Prevention (CDC)

3. Chalder fatigue scale (0-11) not less than 4

Exclusion Criteria:

1. Have any medical history that may cause fatigue before COVID-19 infection, which include but not limited to cardiovascular diseases, chronic lung diseases, dyspnea, cognitive diseases, psychological diseases, chronic liver or renal diseases, cancer, etc.

2. Must chronically taking medicines that may affect the study results.

3. Severe obesity (BMI not less than 45)

4. Alcoholism or drug abuse

5. Allergy to Chinese medicine

6. Pregnancy, or plan to be pregnant, or lactating women